The term of a patent is the
maximum period during which the patent can be enforced. Under current law, a U.S.
patent granting from an application that was filed after June 8, 1995, will
expire twenty years from its earliest effective filing date. The earlier patent
term was seventeen years from the patent issue date. When the law changed,
affected patents were granted a term that was the longer of the two terms calculated
above. The patent term may be shortened due to the filing of a terminal
disclaimer. It may also be adjusted upwards for patent office delays during the
prosecution of the application. In some
cases, the term of a drug or medical device patent (listed in the Orange Book) can
be extended for delays in the FDA’s approval of the use of the associated
product; however, those extensions generally may not exceed 5 years.
U.S. law allows a patent owner to
collect damages accrued up to six years preceding the filing of lawsuit. For
example, if a lawsuit is filed a year after a patent expires, if the plaintiff
prevails in proving infringement, she may claim damages for a period up to five
years preceding the patent’s expiration. This underscores the need for a
product manufacturer to be aware of the expiration dates of all patents that
may be a threat to their ability to make, use, offer for sale, and sell
products.
Note: The patent expiration laws vary by jurisdiction. A patent may expire before its term for a
failure to pay maintenance fee or it may be invalidated during the course of
patent litigation. Patents whose terms are affected by such events are not
covered in this update.
Orange Book and Mobile Technology Patents that expired in the
October 2013:
The table below lists selected
patents that expired in the month of October along with the ownership details
and products covered by these patents.
Patent
Number
|
Title
|
Owner/Assignee
|
Products
Covered
|
Expiration
Date[i]
|
Category
|
5540930 and 5747061
|
Suspension of loteprednol etabonate for
ear, eye, or nose treatment
|
Goldman Sachs
Lending Partners as Collateral Agent
|
Alrex
|
10/25/2013
|
Drug
|
Lotemax
|
|||||
Zylet
|
|||||
5565467
|
Androstenone derivative
|
Smithkline Beecham Corporation
|
Avodart
|
10/15/2013
|
Drug
|
Jalyn
|
|||||
5569672
|
Compounds
|
Beecham Group (as per face page)
|
Bactroban
|
10/29/2013
|
Drug
|
5741523
|
Stabilized prostaglandin E1
|
Pharmacia & Upjohn Company
|
Caverject
|
10/27/2013
|
Drug
|
5869100
|
Extended release clonidine formulation
(tablet)
|
Fulcrum Capital Partners Inc.
|
Jenloga
|
10/13/2013
|
Drug
|
Kapvay
|
|||||
5563175
|
GABA and L-glutamic acid analogs for
antiseizure treatment
|
Northwestern University, Warner-Lambert
Company
|
Lyrica
|
10/08/2013
|
Drug
|
5919455
|
Non-antigenic branched polymer conjugates
|
Pfizer Inc.
|
Macugen
|
10/27/2013
|
Drug
|
6113906
|
Water-soluble non-antigenic polymer
linkable to biologically active material
|
Pfizer Inc.
|
Macugen
|
10/27/2013
|
Drug
|
6090799
|
Method for ameliorating muscle
weakness/wasting in a patient infected with human immunodeficiency virus-type
1
|
Morgan Stanley Senior Funding Inc.
|
Oxandrin
|
10/20/2013
|
Drug
|
5547957
|
Method of treating androgenic alopecia with
5- alpha reductase inhibitors
|
Merck Sharp & Dohme Corp.
|
Propecia
|
10/15/2013
|
Drug
|
5563138
|
Benzoheterocyclic compounds
|
Otsuka Pharmaceutical Company Ltd.
|
Raxar
|
10/08/2013
|
Drug
|
5563142
|
Diaromatic substituted compounds as
anti-HIV-1 agents
|
Pharmacia & Upjohn Company
|
Rescriptor
|
10/08/2013
|
Drug
|
5565473
|
Unsaturated hydroxyalkylquinoline acids as
leukotriene antagonists
|
Merck Sharp & Dohme
Pharmaceuticals
|
Singulair
|
10/15/2013
|
Drug
|
5567817
|
Triazole antifungal agents
|
Pfizer Inc.
|
Vfend
|
10/22/2013
|
Drug
|
5484926
|
HIV protease inhibitors
|
Agouron Pharmaceuticals Inc.
|
Viracept
|
10/07/2013
|
Drug
|
6162812
|
Pharmaceutical compositions containing HIV
protease inhibitors and methods of their use
|
Agouron Pharmaceuticals Inc. (as per
face page)
|
Viracept
|
10/07/2013
|
Drug
|
5569652
|
Dihydrospirorenone as an antiandrogen
|
Bayer Pharma
|
Yasmin
|
10/29/2013
|
Drug
|
Yaz
|
|||||
5490165
|
Demodulation element assignment in a system
capable of receiving multiple signals
|
Qualcomm Inc.
|
Blackberry
8703e
|
10/28/2013
|
Cell Phones, Accessories
|
BlackBerry
Bold 9650 Smartphone - 5.0,
|
|||||
BlackBerry
Curve 9300/9330 Smartphones - BlackBerry Curve Series - 6.0
|
|||||
HTC Touch
diamond 2
|
|||||
Motorola
Sprint
Mobile
Broadband Smart
Device
|
|||||
HTC Smart
phone
|
|||||
5568483
|
Method and apparatus for the formatting of
data for transmission
|
Qualcomm Inc.
|
Blackberry
8703e
|
10/22/2013
|
Cell Phones, Accessories
|
BlackBerry
Bold 9650/9700 Smartphone - 5.0
|
|||||
HTC Smart
phone
|
|||||
HTC Touch
diamond 2
|
|||||
Motorola
Sprint Mobile Broadband Smart Device
|
|||||
5563146
|
Method of treating hyperproliferative
vascular disease
|
Wyeth
|
CYPHER
Sirolimus-eluting Coronary Stent on RAPTORRAIL Rapid Exchange Delivery System
|
10/08/2013
|
Medical Devices
|
CYPHER
Sirolimus-eluting Coronary Stent on RAPTORTM Over-the-Wire
Delivery System
|
|||||
5515379
|
Time slot allocation method
|
Motorola Mobility LLC
|
Motorola
i700plus
|
10/18/2013
|
Cell Phones
|
5558091
|
Magnetic determination of position and orientation
|
Biosense Inc.
|
NAVISTAR DS
Diagnostic/Ablation Catheter
|
10/06/2013
|
Medical Devices
|
Note: The table is sourced from MaxVal’s Patent Marker[ii].
To know if these patents
are litigated or not, use MaxVal’s free online tool Has This Patent Been Litigated? Also available as a free Android app
from the Google Play Store.
[i]
Expected expiration date. This date is
calculated using MaxVal’s Patent Term Estimator, which is a free web-based tool that automatically
calculates patent terms and expiration dates for U.S. utility patents.
[ii]
MaxVal’s Patent Marker provides an online
environment where patentees can virtually mark products and search products for
patent-related information.
No comments:
Post a Comment